Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Columbia Weill Cornell Cancer Centers - Herbert Irving Comprehensive Cancer Center (HICCC), New York

Montefiore Medical Center, The Bronx

Geisinger - Knapper Clinic, Danville

St. Agnes Hospital, Baltimore

Waverly Hem Onc, Cary

Vidant Medical Center, Greenville

Tift Regional, Tifton

Bond Clinic, PA, Winter Haven

Gabrail Cancer Center- Canton Facility, Canton

Prairie Lakes Health Care System Inc., Watertown

North Shore Cancer Research Association-Skokie, Skokie

Edward Cancer Center, Naperville

Southern Illinois University, Springfield

Washington University School of Medicine, St Louis

Clinical Trials of SWLA LLC, Lake Charles

INTEGRIS Southwest Medical Center, Oklahoma City

INTEGRIS Cancer Institute Proton Campus, Oklahoma City

Renovatio Clinical, The Woodlands

Mayo Clinic, Phoenix

University of Southern California, Los Angeles

Innovative Clinical Research Institute, Whittier

Pacific Shores Medical Group, Long Beach

Compassionate Cancer Care Medical Group, Riverside

Ventura County Hematology-Oncology Specialists, Oxnard

Kaiser Permanente Northwest, Portland

Summit Medical Group, Morristown